American Urological Association Annual Meeting
Patients With Low Grade NMIBC Experience Maintained Quality-of-Life With Mitomycin Gel
May 28, 2022
Article
Investigators reported that mitomycin gel was not associated with decrements in urinary symptoms, bloating and flatulence, or malaise, and that sexual function only mildly worsened.
Darolutamide Extends Survival in nmCRPC Regardless of Prior RT or Radical Prostatectomy
May 25, 2022
Article
Darolutamide significantly prolonged metastasis-free survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer with no added toxicity.
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations
May 19, 2022
Article
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Patients With Advanced Prostate Cancer on Relugolix Experience Manageable Toxicity Levels
May 18, 2022
Article
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer.
Patients With Metastatic Urothelial Carcinoma Achieve Superior Survival After Experiencing irAEs With Pembrolizumab
May 17, 2022
Article
In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.
Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADT
May 16, 2022
Article
A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.
Vitamin C Increases Chemotherapy Responses in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
May 16, 2022
Article
Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c.
Men with Intermediate-Risk Prostate Cancer Experience Improved Sexual Function, Urinary Continence Following MRgFUS Therapy
September 24, 2021
Article
Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.
Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC
September 23, 2021
Article
Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.
Higher BMI Linked to Superior Survival in mCRPC
September 20, 2021
Article
Obese men are more likely to have improved overall survival following treatment for mCRPC than man who are overweight or normal weight, analysis finds.